- Home
- NAMI vs DRUG Comparison
NAMI vs DRUG Comparison
Compare NAMI & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMI
- DRUG
- Stock Information
- Founded
- NAMI 2014
- DRUG 2019
- Country
- NAMI China
- DRUG United States
- Employees
- NAMI N/A
- DRUG N/A
- Industry
- NAMI
- DRUG Pharmaceuticals and Biotechnology
- Sector
- NAMI
- DRUG Health Care
- Exchange
- NAMI NYSE
- DRUG Nasdaq
- Market Cap
- NAMI 185.3M
- DRUG 199.7M
- IPO Year
- NAMI 2024
- DRUG N/A
- Fundamental
- Price
- NAMI $0.94
- DRUG $33.46
- Analyst Decision
- NAMI
- DRUG Strong Buy
- Analyst Count
- NAMI 0
- DRUG 7
- Target Price
- NAMI N/A
- DRUG $83.25
- AVG Volume (30 Days)
- NAMI 30.4K
- DRUG 38.7K
- Earning Date
- NAMI 08-12-2025
- DRUG 08-13-2025
- Dividend Yield
- NAMI N/A
- DRUG N/A
- EPS Growth
- NAMI N/A
- DRUG N/A
- EPS
- NAMI 0.10
- DRUG N/A
- Revenue
- NAMI $55,677,960.00
- DRUG N/A
- Revenue This Year
- NAMI N/A
- DRUG N/A
- Revenue Next Year
- NAMI N/A
- DRUG N/A
- P/E Ratio
- NAMI $9.48
- DRUG N/A
- Revenue Growth
- NAMI 7.00
- DRUG N/A
- 52 Week Low
- NAMI $0.86
- DRUG $0.94
- 52 Week High
- NAMI $7.75
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- NAMI N/A
- DRUG 63.96
- Support Level
- NAMI N/A
- DRUG $32.73
- Resistance Level
- NAMI N/A
- DRUG $36.50
- Average True Range (ATR)
- NAMI 0.00
- DRUG 2.23
- MACD
- NAMI 0.00
- DRUG 0.91
- Stochastic Oscillator
- NAMI 0.00
- DRUG 69.90
About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS
Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The company generates revenue by selling its content to hardware manufacturers in China whereby are allowed to install the company's digital educational content on the manufacturers' devices for sale to end users.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.